Chinese Gene Editing Startup EdiGene Raises RMB450 Million

Biotechnology company EdiGene today announced the completion of a RMB450 million yuan in series B financing. This round of financing was led by 3H Health Investment, participated by Sequoia Capital China Fund, Yahui Investment, and Kunlun Capital.

The company’s existing investors IDG Capital, Eli Lilly Asia Fund, Huagai Capital, and Pine Venture Capital also participated in the investment.

EdiGene is a company in the field of gene editing. Based on genome editing technology, it accelerates drug research and develops innovative therapies for a variety of genetic diseases and cancers.

Up to now, EdiGene has four platforms centered on gene editing technology: an in vitro cell gene editing therapy platform for hematopoietic stem cells and T cells, an in vivo gene editing therapy platform based on RNA single-base editing technology, and a targeted A high-throughput genome editing and screening platform for drug development.

Based on these four platforms, the company is pushing R&D projects for genetic diseases and tumors into the clinic.

Allogeneic CAR-T therapy is an important research and development direction. EdiGene CEO Wei Dong said that "Allogeneic T cell therapy is expected to achieve ‘off-the-shelf’ and effective high quality control and lower cost, which will have huge application potential in China and other regions."